Your browser doesn't support javascript.
loading
Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report.
Dunlop, Katharine; Rizvi, Sakina J; Kennedy, Sidney H; Hassel, Stefanie; Strother, Stephen C; Harris, Jacqueline K; Zamyadi, Mojdeh; Arnott, Stephen R; Davis, Andrew D; Mansouri, Farrokh; Schulze, Laura; Ceniti, Amanda K; Lam, Raymond W; Milev, Roumen; Rotzinger, Susan; Foster, Jane A; Frey, Benicio N; Parikh, Sagar V; Soares, Claudio N; Uher, Rudolf; Turecki, Gustavo; MacQueen, Glenda M; Downar, Jonathan.
Afiliação
  • Dunlop K; Department of Psychiatry, Weill Cornell Medicine, New York, NY, USA. kad2032@med.cornell.edu.
  • Rizvi SJ; Institute of Medical Science, University of Toronto, Toronto, ON, Canada.
  • Kennedy SH; ASR Suicide and Depression Studies Unit, St. Michael's Hospital, Toronto, ON, Canada.
  • Hassel S; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
  • Strother SC; Institute of Medical Science, University of Toronto, Toronto, ON, Canada.
  • Harris JK; ASR Suicide and Depression Studies Unit, St. Michael's Hospital, Toronto, ON, Canada.
  • Zamyadi M; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
  • Arnott SR; Centre for Mental Health, University Health Network, Toronto, ON, Canada.
  • Davis AD; Department of Psychiatry and the Mathison Centre for Mental Health Research and Education, University of Calgary, Calgary, AB, Canada.
  • Mansouri F; Rotman Research Institute, Baycrest Health Sciences, Toronto, ON, Canada.
  • Schulze L; Department of Computer Science, University of Alberta, Edmonton, AB, Canada.
  • Ceniti AK; Rotman Research Institute, Baycrest Health Sciences, Toronto, ON, Canada.
  • Lam RW; Rotman Research Institute, Baycrest Health Sciences, Toronto, ON, Canada.
  • Milev R; Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada.
  • Rotzinger S; Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, ON, Canada.
  • Foster JA; Institute of Medical Science, University of Toronto, Toronto, ON, Canada.
  • Frey BN; Institute of Medical Science, University of Toronto, Toronto, ON, Canada.
  • Parikh SV; ASR Suicide and Depression Studies Unit, St. Michael's Hospital, Toronto, ON, Canada.
  • Soares CN; Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.
  • Uher R; Departments of Psychiatry and Psychology, Queen's University, Kingston, ON, Canada.
  • Turecki G; Providence Care Hospital, Kingston, ON, Canada.
  • MacQueen GM; ASR Suicide and Depression Studies Unit, St. Michael's Hospital, Toronto, ON, Canada.
  • Downar J; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
Neuropsychopharmacology ; 45(8): 1390-1397, 2020 07.
Article em En | MEDLINE | ID: mdl-32349119
ABSTRACT
Anhedonia is thought to reflect deficits in reward processing that are associated with abnormal activity in mesocorticolimbic brain regions. It is expressed clinically as a deficit in the interest or pleasure in daily activities. More severe anhedonia in major depressive disorder (MDD) is a negative predictor of antidepressant response. It is unknown, however, whether the pathophysiology of anhedonia represents a viable avenue for identifying biological markers of antidepressant treatment response. Therefore, this study aimed to examine the relationships between reward processing and response to antidepressant treatment using clinical, behavioral, and functional neuroimaging measures. Eighty-seven participants in the first Canadian Biomarker Integration Network in Depression (CAN-BIND-1) protocol received 8 weeks of open-label escitalopram. Clinical correlates of reward processing were assessed at baseline using validated scales to measure anhedonia, and a monetary incentive delay (MID) task during functional neuroimaging was completed at baseline and after 2 weeks of treatment. Response to escitalopram was associated with significantly lower self-reported deficits in reward processing at baseline. Activity during the reward anticipation, but not the reward consumption, phase of the MID task was correlated with clinical response to escitalopram at week 8. Early (baseline to week 2) increases in frontostriatal connectivity during reward anticipation significantly correlated with reduction in depressive symptoms after 8 weeks of treatment. Escitalopram response is associated with clinical and neuroimaging correlates of reward processing. These results represent an important contribution towards identifying and integrating biological, behavioral, and clinical correlates of treatment response. ClinicalTrials.gov NCT01655706.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Citalopram / Transtorno Depressivo Maior Tipo de estudo: Guideline / Prognostic_studies Limite: Humans País como assunto: America do norte Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Citalopram / Transtorno Depressivo Maior Tipo de estudo: Guideline / Prognostic_studies Limite: Humans País como assunto: America do norte Idioma: En Ano de publicação: 2020 Tipo de documento: Article